Summary of COVID-19 obefazimod studies

1. Giavina-Bianchi et al., ABX464 (obefazimod) for patients with COVID-19 at risk for severe disease: miR-AGE, a randomized, double-blind placebo-controlled trial

305 patient obefazimod late treatment RCT: 26% higher ventilation (p=0.81) and 139% higher need for oxygen therapy (p=0.11).
RCT 509 patients with COVID-19 at risk for severe disease showing no benefit with obefazimod (ABX464) 50mg daily for 28 days.
Nov 2023, J. Allergy and Clinical Immunology: Global, https://www.sciencedirect.com/science/article/pii/S2772829323000656, https://c19p.org/giavinabianchi